LOW-VOLUME · FEMALE-LED
oxaprozin Side Effects
oxaprozin (also sold as Daypro) is a LOW-VOLUME FAERS extract #457 of 524 by FAERS report count. Still opens on FEMALE-LED: 75% of sex-coded reports are female (1,459 F / 488 M).
Data updated 2026-05-15
- 2,050
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
oxaprozin reporting skew - 75% of sex-coded reports are female (1,459 F / 488 M). Volume band LOW-VOLUME #457 of 524 by FAERS report count; caseload SIGNAL.
Thinner FAERS extract for oxaprozin (Daypro) (2,050 reports #457 of 524 by FAERS report count). 75% of sex-coded reports are female (1,459 F / 488 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2003–2025). Stamps SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
DRUG HYPERSENSITIVITY leads 386 of 2,050 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (75% of sex-coded rows)
Age peak 45-64 (669 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 80 reports (3.9% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 24 |
| ACUTE KIDNEY INJURY | 14 |
| CHRONIC KIDNEY DISEASE | 14 |
| RENAL FAILURE | 13 |
| HYPERTENSION | 11 |
| ANXIETY | 10 |
| PAIN | 10 |
| FATIGUE | 9 |
| MYOCARDIAL INFARCTION | 9 |
| ASTHENIA | 8 |
| CARDIAC FAILURE CONGESTIVE | 8 |
| END STAGE RENAL DISEASE | 8 |
| OSTEOARTHRITIS | 8 |
| CARDIAC ARREST | 7 |
| CHEST PAIN | 7 |
| PNEUMONIA | 7 |
| ANAEMIA | 6 |
| BACK PAIN | 6 |
| DYSPNOEA | 6 |
| EMOTIONAL DISTRESS | 6 |
Reactions in Hospitalization Reports
Hospitalization mid-share (475, 23.2%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| PAIN | 58 |
| DYSPNOEA | 50 |
| NAUSEA | 47 |
| CHEST PAIN | 45 |
| HYPERTENSION | 45 |
| FALL | 44 |
| ANXIETY | 42 |
| DEPRESSION | 41 |
| DIZZINESS | 38 |
| BACK PAIN | 37 |
| ASTHENIA | 36 |
| PAIN IN EXTREMITY | 35 |
| MYOCARDIAL INFARCTION | 34 |
| OSTEOARTHRITIS | 34 |
| FATIGUE | 33 |
| HEADACHE | 33 |
| ARTHRALGIA | 31 |
| PNEUMONIA | 28 |
| EMOTIONAL DISTRESS | 27 |
How to read oxaprozin FAERS figures (SIGNAL · DEATH-MARKED · HOSP-MID)
FAERS holds 2,050 voluntary reports linked to oxaprozin (Daypro), 2003-2025. Death is listed on 80 (3.9%). Hospitalization appears on 475 (23.2%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with oxaprozin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 2,013 FAERS cases (Δ 37 lighter vs oxaprozin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 2,104 FAERS cases (Δ 54 heavier vs oxaprozin); DEATH-MARKED · HOSP-HEAVY · FEMALE-LED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 1,982 FAERS cases (Δ 68 lighter vs oxaprozin); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 1,978 FAERS cases (Δ 72 lighter vs oxaprozin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 58.2 pp vs oxaprozin's DEATH-MARKED): CASELOAD · HOSP-MID.
oxaprozin stamps SIGNAL · FEMALE-LED; class peers and methodology beat restating the same FAERS caveats on every effects URL.